FIV Protease Antibody (PR3-2): sc-65654

FIV Protease Antibody (PR3-2) is a mouse monoclonal IgG1 antibody that detects the FIV Protease protein of FIV origin by western blotting (WB). Anti-FIV Protease antibody (PR3-2) is available as the non-conjugated format. Feline immunodeficiency virus (FIV) is a lentivirus that poses a significant health risk to domestic cats worldwide, with five distinct subtypes identified based on variations in the viral envelope′s amino acid sequences. FIV Protease plays a crucial role in the viral life cycle, specifically in the processing of viral polyproteins into functional proteins necessary for viral replication. This proteolytic activity is essential for the maturation of the virus, as it ensures the proper assembly of viral components, which ultimately influences the virus′s ability to infect host cells and evade the immune response. The main transmission route of FIV is through deep bite wounds, but can also spread via mucosal surfaces, highlighting the importance of understanding the viral proteins involved in pathogenesis. FIV Protease (PR3-2) monoclonal antibody serves as a valuable tool for researchers studying the mechanisms of FIV infection and the development of potential therapeutic strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FIV Protease Antibody (PR3-2) References:

1. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.  |  Giannecchini, S., et al. 2003. J Virol. 77: 3724-33. PMID: 12610147
2. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.  |  Lin, YC., et al. 2003. J Virol. 77: 6589-600. PMID: 12767979
3. T cell subpopulations mediating inhibition of feline immunodeficiency virus replication in mucosally infected cats.  |  Shimojima, M., et al. 2004. Microbes Infect. 6: 265-71. PMID: 15026013
4. Feline immunodeficiency virus subtypes A, B and C and intersubtype recombinants in Ontario, Canada.  |  Reggeti, F. and Bienzle, D. 2004. J Gen Virol. 85: 1843-1852. PMID: 15218168
5. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer.  |  Sinn, PL., et al. 2005. J Virol. 79: 12818-27. PMID: 16188984
6. Limited efficacy of an inactivated feline immunodeficiency virus vaccine.  |  Dunham, SP., et al. 2006. Vet Rec. 158: 561-2. PMID: 16632531
7. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats.  |  Dean, GA., et al. 2006. J Infect Dis. 193: 1520-7. PMID: 16652280
8. RNA in situ hybridization for the detection of Feline Immunodeficiency Virus in infected cells.  |  Ryan, G., et al. 2006. Southeast Asian J Trop Med Public Health. 37: 106-12. PMID: 16771221
9. Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties.  |  Pancino, G., et al. 1995. Virology. 206: 796-806. PMID: 7856093